Developers of Cardiovascular Drug-Eluting Stents
Company
Stent
Drug
Status
Abbott Vascular Devices
ZoMaxx
Zotarolimus
In clinicals; ZOMAXX II trial approved 6/05
Avantec Vascular (Goodman)
Duraflex
Pimecrolimus
In development
Biosensors International
BioMatrix
Biolimus A9
In trials; Expects CE Mark in 2006
Boston Scientific
Taxus Express2
Paclitaxel
CE Mark 1/03; FDA approval 3/04
Boston Scientific
Taxus Liberté
Paclitaxel
CE Mark 9/05 (launched 1/05); FDA approval expected mid-2006
Conor Medsystems
CoStar
Paclitaxel
CE Marked 2/06
Conor Medsystems
(Next-generation CoStar)
Pimecrolimus
Pimecrolimus licensed from Novartis in [...]
In our April issue of MedMarkets, we cover the current and forecasted market for drug-eluting stents, considering the pending introductions of a number of competitors to established players J&J and Boston Scientific. We also look at the hard successes of biotech in bringing products to market and the growing success the industry is having in [...]
Last week, I wrote the white paper, High Growth Medical Technologies, based on looking at different technologies I have seen and believe have excellent prospects for growth in the near term. I have since edited the white paper to not only clean up some typos but to also add a section on additional opportunities and [...]
The proosal by CMS to reduce by up to 30% the reimbursement to hospitals for cardiac devices arises from a compelling need to reduce the clearly high costs associated with these devices (stents, defibrillators, etc.). Given the size of the proposed cuts, however, and their impact on device makers and hospitals, their negative reaction (see [...]
This is preliminary(!) list of the companies involved in nanotech and/or MEMS with at least a minimum level of activity in applying the technologies to medical applications. This list was updated from a previous report by MMD, but still may included a number of companies (not yet edited out) who ultimately were unable to sustain [...]
The April 2006 issue of MedMarkets updates the market for drug-eluting stents. We also review the status of the biotech industry, considering a report from Ernst & Young (Beyond Borders: The Global Biotechnology Report) and other data on this ever-optimistic industry. (BTW, I found it particularly curious that the E&Y report referred to this year [...]
The most rewarding aspect of tracking medical technology markets is witnessing the innovation that emerges as entrepreneurs device solutions to healthcare problems that sometimes providers didn’t know exist (or at least couldn’t put their finger on).
We put together a small white paper looking at some of the high growth medical technologies we see for the [...]
The market for products worldwide in the management of diabetes is the subject of an analysis done by MMD at the end of 2005. While a plethora of studies are available on markets for diabetes-related products, our analysis succeeds uniquely by looking at both established and developing technologies with a more critical eye and doing [...]
News came out last week (published in Lancet) on the successes achieved by well-known researcher Dr. Anthony Atala, professor at the Wake Forest Institute of Regenerative Medicine, in the development of pediatric bladders engineered from patients’ own cells.
The development of bioengineered organs, which faces many technological hurdles but also holds tremendous promise, was part of [...]
These are recent startups I am reporting on in the April issue of my newsletter. As always, there’s no guarantee (or endorsement on my part) that any of these will succeed:
Company
Principals or Investors
Location
Technology
Founded
Bioasssessments, LLC
Peter Hyde, Christopher Hyde
Elkton, MD
Real-time angiotensin monitor for salt sensitivity
2006
Neotract, Inc.
New Enterprise Associates
Palo Alto, CA
Surgical urological devices
2005
NeuroLife Noninvasive Solutions
Daniel McChesney, MD
Pittsburgh, PA
Noninvasive [...]
